Berman David M

Berman David M, Head of R&D, has demonstrated a clear selling bias in his recent transactions involving Immunocore Holdings plc (IMCR), the sole company in his trading history. Over 40 reported trades, his total sales amount to $18.4 million, dwarfing his $6.6 million in purchases. The most recent activity—spanning from September 2025 to February 2026—shows an uninterrupted pattern of disposals, with 14 sales and no buys. Notably, his November 2025 transactions included multiple high-value sales, including a $2.78 million disposal on November 26 and a $721,340 sale the following day. These were followed by additional sales in December, including a $1.26 million transaction on December 4. His most recent sale occurred on February 18, 2026, worth $192,967. The filings also reveal that many of Berman’s sales were accompanied by market acquisitions (coded "M"), likely tied to option exercises or other equity compensation events. For example, his $1.26 million sale on December 4, 2025, coincided with a $547,213 market acquisition, suggesting a sell-to-cover transaction. This pattern indicates that while Berman has been reducing his stake in IMCR, some sales are linked to the monetization of vested equity. The absence of recent purchases and the sustained selling activity—particularly the multi-million-dollar disposals—suggest a consistent divestment trend rather than accumulation. The data reflects a disciplined approach to unwinding his position in IMCR over time.